Granules India Ltd. Announces Q4FY25 Results: Revenue Growth and Strong PAT
Mumbai: Granules India Ltd., a vertically integrated pharmaceutical company, has announced its financial results for Q4FY25 and FY25. The company reported a revenue from operations of INR 11,974 Mn, up 2% YoY, and a PAT of INR 1,520 Mn, up 17% YoY.
Key Highlights
- Revenue Growth: 2% YoY growth in revenue from operations, driven by a sustained increase in formulations’ share.
- Formulations Growth: 18% growth in formulations revenue, despite a slowdown in productivity at the Gagillapur facility due to US FDA remediation activities.
- Revenue Share: North America contributed 79% of revenue in Q4 FY25, up from 70% in Q4 FY24.
- Segment-wise Revenue: API (12%), PFI (10%), and Finished Dosages (77%).
Financial Performance
- EBITDA: INR 2,524 Mn, down 1% YoY.
- ROCE: 16.6%, up from 16.5% YoY.
- Net Debt: Reduced by INR 1,360 Mn to INR 7,061 Mn.
- Net Debt to EBITDA: 0.75x.
Krishna Prasad Chigurupati, Chairman & Managing Director, said: “We are pleased to report a resilient bottom line and cash flow performance this year, despite sales remaining steady. Our strong financial performance reflects the success of our strategic initiatives, particularly our focus on enhancing our product mix by prioritizing high-margin offerings and expanding our portfolio of non-legacy molecules.”
Financial Summary (All numbers in INR Mn.)
| QUARTERLY CONSOLIDATED FINANCIALS | Q4FY25 | Q3FY25 | Growth (QoQ) | Q4FY24 | Growth (YoY) |
| Revenue from Operations | 11,974 | 11,377 | 5% | 11,758 | 2% |
| EBITDA | 2,524 | 2,303 | 10% | 2,557 | (1%) |
| EBITDA % | 21% | 20% | 22% | ||
| PAT | 1,520 | 1,176 | 29% | 1,296 | 17% |
| PAT % | 13% | 10% | 11% |
| ANNUAL CONSOLIDATED FINANCIALS | FY25 | FY24 | Growth (YoY) |
| Revenue from Operations | 44,816 | 45,064 | (1%) |
| EBITDA | 9,452 | 8,560 | 10% |
| EBITDA % | 21% | 19% | |
| PAT | 5,015 | 4,053 | 24% |
| Net Profit Margin | 11% | 9% |
